ATE429230T1 - CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT - Google Patents

CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT

Info

Publication number
ATE429230T1
ATE429230T1 AT03740769T AT03740769T ATE429230T1 AT E429230 T1 ATE429230 T1 AT E429230T1 AT 03740769 T AT03740769 T AT 03740769T AT 03740769 T AT03740769 T AT 03740769T AT E429230 T1 ATE429230 T1 AT E429230T1
Authority
AT
Austria
Prior art keywords
cancer treatment
chinazoline derivatives
derivatives
chinazoline
treatment
Prior art date
Application number
AT03740769T
Other languages
German (de)
Inventor
Laurent Hennequin
Kevin Foote
Keith Gibson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0215825A external-priority patent/GB0215825D0/en
Priority claimed from GB0312897A external-priority patent/GB0312897D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE429230T1 publication Critical patent/ATE429230T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.
AT03740769T 2002-07-09 2003-07-04 CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT ATE429230T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0215825A GB0215825D0 (en) 2002-07-09 2002-07-09 Quinazoline derivatives
GB0312897A GB0312897D0 (en) 2003-06-05 2003-06-05 Quinazoline derivatives
PCT/GB2003/002874 WO2004004732A1 (en) 2002-07-09 2003-07-04 Quinazoline derivatives for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE429230T1 true ATE429230T1 (en) 2009-05-15

Family

ID=30117104

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03740769T ATE429230T1 (en) 2002-07-09 2003-07-04 CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT

Country Status (7)

Country Link
US (1) US7504408B2 (en)
EP (1) EP1528925B1 (en)
JP (1) JP2005536486A (en)
AT (1) ATE429230T1 (en)
AU (1) AU2003281193A1 (en)
DE (1) DE60327323D1 (en)
WO (1) WO2004004732A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
CA2503371C (en) 2002-11-04 2011-01-11 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
EA013904B1 (en) 2003-12-18 2010-08-30 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
NI200700147A (en) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv QUINAZOLINE DERIVATIVES KINE INHIBITORS TARGETING MULTIP
JO3088B1 (en) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv Macrocyclic Quinazoline derivatives and their use as MTKI
CN101490060B (en) * 2006-07-13 2012-04-11 詹森药业有限公司 Mtki quinazoline derivatives
UY31137A1 (en) * 2007-06-14 2009-01-05 Smithkline Beecham Corp DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THE PI3 QUINASA
TWI577671B (en) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN105037279B (en) * 2015-06-25 2017-11-03 贵州大学 4 N substituted quinazolines analog derivatives of the structure containing pentadienone and preparation and application
MX2018004109A (en) 2015-10-05 2018-09-27 Univ Columbia Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies.
CN105753793B (en) * 2016-01-19 2018-09-04 河北医科大学 Fragrant formyl urea coupling quinazoline compounds and preparation method thereof, pharmaceutical composition and medicinal usage

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
IL89028A0 (en) * 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
DK0584222T3 (en) * 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono and bicyclic aryl and heteroaryl compounds that inhibit EGF and / or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
PT100905A (en) * 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
ATE227283T1 (en) 1996-07-13 2002-11-15 Glaxo Group Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
CA2344169C (en) 1998-09-29 2011-07-19 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
KR20080015482A (en) * 1999-02-10 2008-02-19 아스트라제네카 아베 Quinazolin derivatives as angiogenesis inhibitors
EP1218356A1 (en) * 1999-09-21 2002-07-03 AstraZeneca AB Quinazoline compounds and pharmaceutical compositions containing them
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
KR100821446B1 (en) * 2000-08-21 2008-04-10 아스트라제네카 아베 Quinazoline derivatives
DE60229046D1 (en) 2001-04-19 2008-11-06 Astrazeneca Ab CHINAZOLINE DERIVATIVES
ATE341545T1 (en) 2001-07-16 2006-10-15 Astrazeneca Ab QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS
GB0128109D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
GB0128122D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
AU2002365664A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives as antitumour agents
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
JP2005536486A (en) 2005-12-02
DE60327323D1 (en) 2009-06-04
EP1528925A1 (en) 2005-05-11
WO2004004732A1 (en) 2004-01-15
US20050250797A1 (en) 2005-11-10
US7504408B2 (en) 2009-03-17
AU2003281193A1 (en) 2004-01-23
EP1528925B1 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
NO20025792D0 (en) Quinazoline derivatives for the treatment of tumors
ATE341545T1 (en) QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS
ATE452129T1 (en) N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES
MY129809A (en) Quinazoline derivatives
ATE409185T1 (en) QUINAZOLINE DERIVATIVES
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
ATE353888T1 (en) CHINAZOLINE DERIVATIVES
TW200510392A (en) Chemical compounds
BR0315580A (en) Methylene Urea Derivatives
WO2004108715A8 (en) 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity
DE60001974D1 (en) DERIVATIVES OF FLAVONES, XANTHONES AND CUMARINES
CY1108932T1 (en) Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases
TW200505452A (en) Chemical compounds
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
ATE429230T1 (en) CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT
DE60001586D1 (en) DIPHENYL-PIPERIDINE DERIVATIVES
WO2003053960A3 (en) Quinline derivates and their use as mek inhibitors
ATE424200T1 (en) SOLUBILIZED TOPOISOMERASE POISON AGENT
TW200420567A (en) Quinazoline derivatives
ATE482955T1 (en) AZABICYCLOOCTAN-3 DERIVATIVES AND THEIR USE
DE602004022783D1 (en) Hetereocyclic urea derivatives for the treatment of pain.
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
MXPA05011671A (en) Novel aniline derivatives, their manufacture and use as pharmaceutical agents.
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents
TW200612914A (en) Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties